Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Tumor Virus Infections D014412 8 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Pain D010146 64 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Pulmonary Fibrosis D011658 24 associated lipids
Wounds and Injuries D014947 20 associated lipids
Pleurisy D010998 20 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Leslie CC and Detty DM Arachidonic acid turnover in response to lipopolysaccharide and opsonized zymosan in human monocyte-derived macrophages. 1986 Biochem. J. pmid:3098232
Prunieras M Melanocytes, melanogenesis, and inflammation. 1986 Int. J. Dermatol. pmid:2433237
Schleimer RP et al. Selective inhibition of arachidonic acid metabolite release from human lung tissue by antiinflammatory steroids. 1986 J. Immunol. pmid:3082976
Wardlow ML et al. Substrate specificity and partial characterization of the PAF-acylhydrolase in human serum that rapidly inactivates platelet-activating factor. 1986 J. Immunol. pmid:3514760
Lad PM et al. A step sensitive to pertussis toxin and phorbol ester in human neutrophils regulates chemotaxis and capping but not phagocytosis. 1986 FEBS Lett. pmid:3699167
Böhm R and Giessler AJ [Thrombocyte aggregation inhibitors. A new class of active substances]. 1986 Pharmazie pmid:3515372
Viero P et al. Defective platelet aggregation induced by platelet activating factor in myeloproliferative disorders: deficiency of an aspirin-independent mechanism? 1986 Haemostasis pmid:3699584
Etienne A et al. In vivo inhibition of plasma protein leakage and Salmonella enteritidis-induced mortality in the rat by a specific paf-acether antagonist: BN 52021. 1986 Agents Actions pmid:3515870
Nunez D et al. Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988. 1986 Eur. J. Pharmacol. pmid:3086108
Oxholm P and Winther K Thrombocyte involvement in immune inflammatory reactions. 1986 Allergy pmid:3515999
Wallace JL and Whittle BJ Picomole doses of platelet-activating factor predispose the gastric mucosa to damage by topical irritants. 1986 Prostaglandins pmid:3726156
DeFeudis FV Possible relationship between the syntheses of endothelium-derived relaxing factor (EDRF) and PAF-acether. 1986 Gen. Pharmacol. pmid:3516791
Eche N et al. Platelet aggregating and procoagulant activities of cultured human breast cancer cells (FAM). 1986 Thromb. Res. pmid:3726808
Camussi G Potential role of platelet-activating factor in renal pathophysiology. 1986 Kidney Int. pmid:3517457
Hoffman DR et al. The role of platelet-activating factor in human fetal lung maturation. 1986 Am. J. Obstet. Gynecol. pmid:3728606
Mastacchi R et al. Interaction of a new low molecular weight heparin (OP/LMWH) with human platelets. 1986 Agents Actions pmid:3518359
Simmet T and Peskar BA Eicosanoids and the coronary circulation. 1986 Rev. Physiol. Biochem. Pharmacol. pmid:3520775
Conrad GW and Rink TJ Platelet activating factor raises intracellular calcium ion concentration in macrophages. 1986 J. Cell Biol. pmid:3733874
Moudgil GC Anaesthesia and allergic drug reactions. 1986 Can Anaesth Soc J pmid:3521800
Imura Y et al. Possible role of platelet activating factor (PAF) in disseminated intravascular coagulation (DIC), evidenced by use of a PAF antagonist, CV-3988. 1986 Life Sci. pmid:3741541
Foegh ML et al. Prolongation of cardiac allograft survival with BN 52021, a specific antagonist of platelet-activating factor. 1986 Transplantation pmid:3523888
Kertscher HP and Ostermann G [Synthesis and thrombocyte aggregating action of stereoisomers of PAF-acether]. 1986 Pharmazie pmid:3786385
Touvay C et al. Characterization of platelet activating factor (PAF)-acether-induced contractions of guinea-pig lung strips by selected inhibitors of arachidonic acid metabolism and by PAF-acether antagonists. 1986 Immunopharmacology pmid:3021651
Powling MJ and Hardisty RM Differential effects of 12-O-tetradecanoylphorbol 13-acetate on platelet responses to various agonists in the presence and absence of extracellular Ca2+. 1986 Thromb. Res. pmid:3787566
Wardlaw AJ et al. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. 1986 J. Clin. Invest. pmid:3023451
Buxton DB et al. Specific antagonists of platelet activating factor-mediated vasoconstriction and glycogenolysis in the perfused rat liver. 1986 Biochem. Pharmacol. pmid:3754140
Foegh ML et al. The causal role of PAF and leukotrienes in acute cardiac allograft rejection in rats. 1986 Pharmacol Res Commun pmid:3534895
Toyofuku T et al. Effects of ONO-6240, a platelet-activating factor antagonist, on endotoxin shock in unanesthetized sheep. 1986 Prostaglandins pmid:3754344
O'Flaherty JT Age dependency of the inflammatory response. 1986 Lab. Invest. pmid:3537520
Touvay C et al. Inhibition of antigen-induced lung anaphylaxis in the guinea-pig by BN 52021 a new specific paf-acether receptor antagonist isolated from Ginkgo biloba. 1986 Agents Actions pmid:3754380
Sybertz EJ et al. AGEPC, a vasodilator phospholipid with profound circulatory actions. 1986 Prog. Clin. Biol. Res. pmid:3538024
Sugatani J and Hanahan DJ Characterization of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (AGEPC)-induced protein phosphorylation in rabbit platelets: inhibitory effects of AGEPC analogs. 1986 Arch. Biochem. Biophys. pmid:3754710
McGowan HM et al. Increased aortic PGI2 and plasma lyso-PAF in the unclipped one-kidney hypertensive rat. 1986 Am. J. Physiol. pmid:3538908
Hsueh W et al. Platelet activating factor-induced ischemic bowel necrosis: the effect of PAF antagonists. 1986 Eur. J. Pharmacol. pmid:3754817
Hemmendinger S et al. [Methods of studying platelet function. Biological markers of the activation of human platelets in vivo and in vitro]. 1986 Ann. Biol. Clin. (Paris) pmid:3538949
Okamoto M et al. Platelet activating factor (PAF) involvement in endotoxin-induced thrombocytopenia in rabbits: studies with FR-900452, a specific inhibitor of PAF. 1986 Thromb. Res. pmid:3754990
Zimmerman GA and Klein-Knoeckel D Human endothelial cells inhibit granulocyte aggregation in vitro. 1986 J. Immunol. pmid:3009611
Villamediana LM et al. Effects of the platelet-activating factor antagonist BN 52021 on the hemodynamics of rats with experimental cirrhosis of the liver. 1986 Life Sci. pmid:3755490
Garay R and Braquet P Involvement of K+ movements in the membrane signal induced by PAF-acether. 1986 Biochem. Pharmacol. pmid:3755602
Pfueller SL and David R Different platelet specificities of heparin-dependent platelet aggregating factors in heparin-associated immune thrombocytopenia. 1986 Br. J. Haematol. pmid:3756098
Hoffman DR et al. Cytotoxicity and metabolism of alkyl phospholipid analogues in neoplastic cells. 1986 Cancer Res. pmid:3756924
Alloatti G et al. Effect of platelet-activating factor (PAF) on human cardiac muscle. 1986 Int. Arch. Allergy Appl. Immunol. pmid:3941007
Porcellini G [Platelet-activating factor: a new biochemical and pharmacologic frontier]. 1986 Clin Ter pmid:3720244
Wallace JL and Whittle BJ Prevention of endotoxin-induced gastrointestinal damage by CV-3988, an antagonist of platelet-activating factor. 1986 Eur. J. Pharmacol. pmid:3720841
Oh-ishi S et al. Suppression of phorbol myristate acetate-induced pleurisy by CV-3988, an antagonist of platelet-activating factor. 1986 Chem. Pharm. Bull. pmid:3829203
Handley DA et al. Vascular responses of platelet-activating factor in the Cebus apella primate and inhibitory profiles of antagonists SRI 63-072 and SRI 63-119. 1986 Immunopharmacology pmid:3733419
Flower RJ Background and discovery of lipocortins. 1986 Agents Actions pmid:2938452
Ramesha CS and Pickett WC Measurement of sub-picogram quantities of platelet activating factor (AGEPC) by gas chromatography/negative ion chemical ionization mass spectrometry. 1986 Biomed. Environ. Mass Spectrom. pmid:2938649
Resink TJ et al. The influence of activating hormones on human platelet membrane Ca2+-ATPase activity. 1986 Biochem. Biophys. Res. Commun. pmid:2943273
Gay JC et al. Modulation of neutrophil oxidative responses to soluble stimuli by platelet-activating factor. 1986 Blood pmid:3006836
Thomas MJ et al. Desorption chemical ionization mass spectrometry of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholines and analogues. 1986 J. Lipid Res. pmid:3958619
Stimler-Gerard NP Parasympathetic stimulation as a mechanism for platelet-activating factor-induced contractile responses in the lung. 1986 J. Pharmacol. Exp. Ther. pmid:3958964
Wade PJ et al. Effect of calcium and calcium antagonists on [3H]-Paf-acether binding to washed human platelets. 1986 Thromb. Res. pmid:3961730
Parente L et al. The effect of glucocorticoids on lyso-PAF formation in vitro and in vivo. 1986 Agents Actions pmid:3962774
Tarayre JP et al. Inflammatory action of PAF-acether in the rat pleural cavity. 1986 Agents Actions pmid:3962789
Blank ML et al. Metabolism of platelet activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) and 1-alkyl-2-acetyl-sn-glycerol by human endothelial cells. 1986 Biochim. Biophys. Acta pmid:3707974
Tarayre JP et al. Exudative, cellular and humoral reactions to platelet-activating factor (PAF-acether) in the pleural cavity of rats. 1986 Eur. J. Pharmacol. pmid:3755401
Kikawa Y et al. Leukotriene B4 biosynthesis in polymorphonuclear leukocytes from blood of umbilical cord, infants, children, and adults. 1986 Pediatr. Res. pmid:3012451
Burhop KE et al. Platelet-activating factor increases lung vascular permeability to protein. 1986 J. Appl. Physiol. pmid:3804927
Bussolino F et al. Production of platelet-activating factor by chick retina. 1986 J. Biol. Chem. pmid:3023352
Cox CP Effects of CV-3988, an antagonist of platelet-activating factor (PAF), on washed rabbit platelets. 1986 Thromb. Res. pmid:2421432
Schleimer RP et al. Characterization of inflammatory mediator release from purified human lung mast cells. 1986 Am. Rev. Respir. Dis. pmid:3485946
Okamoto M et al. Studies of platelet activating factor (PAF) antagonists from microbial products. I. Bisdethiobis(methylthio)gliotoxin and its derivatives. 1986 Chem. Pharm. Bull. pmid:2421923
Okamoto M et al. Studies of platelet activating factor (PAF) antagonists from microbial products. II. Pharmacological studies of FR-49175 in animal models. 1986 Chem. Pharm. Bull. pmid:2421924
Hsueh W et al. Platelet-activating factor-induced ischemic bowel necrosis. An investigation of secondary mediators in its pathogenesis. 1986 Am. J. Pathol. pmid:3080895
Robertson DN and Smith GM CV3988 inhibits in vivo platelet aggregation induced by PAF-acether and collagen. 1986 Eur. J. Pharmacol. pmid:3709663
Darius H et al. Role of platelet-activating factor-acether in mediating guinea pig anaphylaxis. 1986 Science pmid:3082008
Kohayakawa M and Inoue K Augmentation of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF)-induced human platelet activation by C-reactive protein. 1986 Thromb. Res. pmid:3083530
Morley J et al. Effects of ketotifen upon responses to platelet activating factor: a basis for asthma prophylaxis. 1986 Ann Allergy pmid:3083731
McIntosh TK and Faden AI Thyrotropin-releasing hormone (TRH) and circulatory shock. 1986 Circ. Shock pmid:3084122
Montrucchio G et al. Intravascular release of platelet-activating factor during atrial pacing. 1986 Lancet pmid:2874319
Hackenthal E and Taugner R Hormonal signals and intracellular messengers for renin secretion. 1986 Mol. Cell. Endocrinol. pmid:2875004
Swingle KF and Reiter MJ Inhibition of Paf-acether-induced edema of the rat's paw. 1986 Agents Actions pmid:2875631
Ghezzi E Autacoids and some mediators in allergic and non allergic forms. 1986 Boll Ist Sieroter Milan pmid:2877678
Homburger HA Diagnosis of allergy: in vitro testing. 1986 Crit Rev Clin Lab Sci pmid:2426037
Pécoud A and Frei PC [Developmental trends in allergologic-immunologic research]. 1986 Internist (Berl) pmid:2427469
Raphael GD and Metcalfe DD Mediators of airway inflammation. 1986 Eur J Respir Dis Suppl pmid:2429857
Yoshida J et al. A platelet-aggregating and hypotensive phospholipid isolated from bovine brain. 1986 J. Pharm. Pharmacol. pmid:2880959
Mossmann H et al. Effect of platelet-activating factor on human polymorphonuclear leukocyte enhancement of chemiluminescence and antibody-dependent cellular cytotoxicity. 1986 J. Leukoc. Biol. pmid:3455715
Mehta J et al. Biphasic effects of platelet-activating factor on coronary blood flow in anesthetized dog. 1986 Prostaglandins Leukot Med pmid:3456620
McIntyre TM et al. Leukotrienes C4 and D4 stimulate human endothelial cells to synthesize platelet-activating factor and bind neutrophils. 1986 Proc. Natl. Acad. Sci. U.S.A. pmid:3457383
Di Marzo V et al. The effect of vasoactive intestinal peptide and calcitonin gene-related peptide on peptidoleukotriene release from platelet activating factor stimulated rat lungs and ionophore stimulated guinea pig lungs. 1986 Biochem. Int. pmid:2432897
Oh S et al. Inflammatory effects of acetylglycerylether phosphorylcholine: vascular permeability increase and induction of pleurisy in rats. 1986 Prostaglandins Leukot Med pmid:3459197
Newhouse MT and Sears MR Platelet activating factor, ketotifen and asthma. 1986 N. Z. Med. J. pmid:3462569
Chignard M et al. Direct evidence for the existence of a neutrophil-derived platelet activator (neutrophilin). 1986 Proc. Natl. Acad. Sci. U.S.A. pmid:3464972
Hahn HL et al. Effects of platelet activating factor on tracheal mucus secretion, on airway mechanics and on circulating blood cells in live ferrets. 1986 Eur J Respir Dis Suppl pmid:3465554
Morley J and Sanjar S Ketotifen and asthma. 1986 N. Z. Med. J. pmid:3466080
Godfroid JJ et al. Synthesis of ether phospholipids. 1986 Pharmacol Res Commun pmid:3774838
Page CP Platelet activating factor, ketotifen and asthma. 1986 N. Z. Med. J. pmid:3466093
Kloprogge E and Akkerman JW Platelet-activating factor (PAF-acether) induces high- and low-affinity binding of fibrinogen to human platelets via independent mechanisms. 1986 Biochem. J. pmid:3101672
PAF and leukotrienes '85. Proceedings of the meeting. Paris, September 27th 1985. 1986 Pharmacol Res Commun pmid:3774839
Vilain B et al. Pharmacological control of the in vivo passive anaphylactic shock by the PAF-acether antagonist compound BN 52021. 1986 Pharmacol Res Commun pmid:3774840
Bessin P PAF-acether and leukotriene participation in acute circulatory shock. 1986 Pharmacol Res Commun pmid:3774841
Goldstein RE et al. Coronary and pulmonary vascular effects of leukotrienes and PAF-acether. 1986 Pharmacol Res Commun pmid:3774842
Plante GE et al. Hemodynamic effects of PAF-acether. 1986 Pharmacol Res Commun pmid:3774843
Sanchez Crespo M et al. Evidence of a role for PAF-acether in the pathophysiology of the shock state. 1986 Pharmacol Res Commun pmid:3774844
Adnot S et al. Interference of BN 52021, a PAF-acether antagonist, with endotoxin-induced hypotension in the guinea-pig. 1986 Pharmacol Res Commun pmid:3774845
Rainsford KD Relative roles of leukotrienes and platelet activating factor in experimentally-induced gastric ulceration. 1986 Pharmacol Res Commun pmid:3774846
Page CP and Morley J Evidence favouring PAF rather than leukotrienes in the pathogenesis of asthma. 1986 Pharmacol Res Commun pmid:3774847
Lee TC et al. A new de novo pathway for the formation of 1-alkyl-2-acetyl-sn-glycerols, precursors of platelet activating factor. Biochemical characterization of 1-alkyl-2-lyso-sn-glycero-3-P:acetyl-CoA acetyltransferase in rat spleen. 1986 J. Biol. Chem. pmid:3007498